YOUR CART
The ErbB-2 proto-oncogene, also called Neu, EGFR-2 or HER-2, is a member of the transmembrane receptor tyrosine kinase family, which also includes EGF receptor and EGFR-3 (HER-3 or ErbB-3). Although, ErbB-2 does not have any known high-affinity ligands, its kinase activity can be activated without ligand by either overexpression or heteroassociation with other members of the ErbB family. Amplification of the ErbB-2 gene and overexpression of its product has been detected in almost 40% of primary human breast tumors, which correlates with poor prognosis in node positive breast cancer. ErbB-2 overexpression is also observed in ovarian, gastric, salivary and non-small cell lung carcinomas. Because of this, ErbB-2 is one of the major drug targets for breast cancer and other cancer treatments.
Figure 1: Monitoring total- and phospho-ErbB-2 using FACE.
The FACE ErbB-2 (Y1248) and ErbB-2 (Y877) Kits were used to assay the levels of total and phosphorylated ErbB-2 contained within untreated or EGF treated A-431 cells.
Antibody Specificities
The FACE ErbB-2 (Y877) Kit contains a phospho-ErbB-2 antibody that was raised in rabbit against a synthetic phospho-peptide corresponding to residues surrounding phosphorylated Tyr877 of human ErbB-2 and recognizes ErbB-2 only when phosphorylated at Tyr877. The FACE ErbB-2 (Y1248) Kit contains a phospho-ErbB-2 antibody that was raised in rabbit against a synthetic phospho-peptide corresponding to residues surrounding phosphorylated Tyr1248 of human ErbB-2 and recognizes ErbB-2 only when phosphorylated at Tyr1248. The total-ErbB-2 antibody supplied in the FACE ErbB-2 Kits recognizes ErbB-2 protein regardless of its phosphorylation site.
